Regulation of the anti-phospholipid response in SLE

SLE 抗磷脂反应的调节

• 批准号: 8415927
• 负责人: Anne Davidson
• 金额: $ 39.56万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-02-01 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8415927
• 关键词: Address; Affinity; Alleles; Antibodies; Antibody Formation; Anticoagulation; Antigen-Antibody Complex; Antiphospholipid Antibodies; Antiphospholipid Syndrome; Apoptosis; Apoptotic; Autoantibodies; Autoimmune Process; B cell repertoire; B-Cell Activation; B-Lymphocyte Subsets; B-Lymphocytes; Blood Clot; Blood coagulation; Bone Marrow; CD28 gene; Cardiolipins; Cell Death; Cell Maturation; Cell Survival; Cells; Ceramides; Chimera organism; Clinical; Clinical Trials; Coagulation Process; Complement; Data; Dendritic Cells; Development; Disease; Endosomes; Endothelial Cells; Endothelium; Event; Fc Receptor; Female; Fostering; General Population; Genes; Genetic; Goals; Human; IRAK1 gene; Immune response; Immune system; Immunoglobulin Class Switching; Immunoglobulin G; Individual; Inflammation; Inflammation Mediators; Interferon-alpha; Interferons; Ligation; Lupus; Maps; Mediating; Mus; Myelogenous; Nephritis; Nucleic Acids; Outcome; Pathogenicity; Pathway interactions; Patients; Phospholipids; Plasma Cells; Process; Production; Proliferative Glomerulonephritis; RNA; Recurrence; Regulation; Risk; Role; STAT4 gene; Second Messenger Systems; Serum; Signal Transduction; Staging; Stress; Syndrome; Systemic Lupus Erythematosus; T-Cell Activation; T-Lymphocyte; TALL-1 protein; TLR7 gene; Testing; Therapeutic immunosuppression; Thrombocytopenia; Thrombophilia; Thrombosis; Thrombus; Tissues; To autoantigen; Transgenic Organisms; Up-Regulation; acid sphingomyelinase; autoreactive B cell; base; cytokine; effective therapy; fetal; genome wide association study; human disease; immune function; in vivo; male; mouse model; novel therapeutics; overexpression; particle; public health relevance; research study; response; second messenger

DESCRIPTION (provided by applicant): The goal of this proposal is to determine the mechanisms for loss of B cell tolerance to phospholipids and mechanisms for tissue damage by anti-phospholipid antibodies in NZW/BXSB F1 (W/B) mice that develop both proliferative glomerulonephritis and anti-phospholipid syndrome. Disease is accelerated in male W/B mice that carry the Yaa locus containing a reduplication of the TLR7 gene. We have shown that T cell help is required for initial activation of anti-phospholipid B cells and induction of high affinity IgG autoantibodies. Our proposal is based on the following hypotheses: 1) Over-expression of TLR7 alters either B cell selection or B cell activation threshold, thus rendering naove B cells more prone to the T cell activation that is required for disease initiation and production of clas switched autoantibodies. 2) Immune complex formation and opsonization of apoptotic particles by IgG anti-phospholipid antibodies results in delivery of nucleic acids to TLR containing endosomes. Engagement of TLRs induces both IFN1 that fosters plasma cell maturation and BAFF that enhances B cell survival and class switching; disease can then be propagated by T cell independent mechanisms that are prominent in males bearing excess TLR7. Because excess IFN1 production is a feature of SLE and IFN1 induces upregulation of TLR7, particularly in females, similar mechanisms may pertain in individuals with the IFN signature even though genetic TLR7 overexpression has not been found in humans with SLE. To address these hypotheses, we will use mice with an autoreactive transgenic heavy chain and examine B cell selection at sequential stages of the B cell developmental pathway. This strategy will allow us to examine the role of intrinsic alterations in B cell signaling, exogenous signals from the innate immune system and T cell help in the initial loss of tolerance to autoantigens and in the perpetuation of the anti- phospholipid response. Our data will also help determine why anti-phospholipid syndrome fails to respond to conventional immunosuppressive therapies and help suggest new strategies for treating this devastating syndrome. Our third hypothesis is that pathogenic autoantibodies alone can cause the manifestations of the anti- phospholipid syndrome that are mediated by Fc receptor or complement dependent mechanisms but that the formation of thromboses requires other inflammatory mediators to activate the endothelium. We will test the hypothesis that one mechanism for this "second hit" is endothelial cell death mediated via the ceramide pathway. Our long term goal is to define the interactions of the crucial pathways that contribute to induction and propagation of the anti-phospholipid syndrome so as to best devise individualized therapies for patients with SLE.

描述（由申请方提供）：本提案的目的是确定发生增殖性肾小球肾炎和抗磷脂综合征的NZW/BXSB F1（W/B）小鼠中B细胞对磷脂耐受性丧失的机制和抗磷脂抗体引起组织损伤的机制。在携带含有TLR 7基因重复的Yaa基因座的雄性W/B小鼠中，疾病加速。我们已经表明，T细胞的帮助是需要的抗磷脂B细胞的初始激活和高亲和力IgG自身抗体的诱导。我们的建议基于以下假设：1）TLR 7的过表达改变B细胞选择或B细胞活化阈值，从而使幼稚B细胞更倾向于疾病起始和类别转换自身抗体产生所需的T细胞活化。 2)免疫复合物形成和通过IgG抗磷脂抗体对凋亡颗粒的调理作用导致核酸递送至含有TLR的内体。TLR的参与诱导促进浆细胞成熟的IFN 1和增强B细胞存活和类别转换的BAFF;然后疾病可以通过T细胞非依赖性机制传播，该机制在携带过量TLR 7的男性中是突出的。 由于过量的IFN 1产生是SLE的一个特征，并且IFN 1诱导TLR 7的上调，特别是在女性中，即使在SLE患者中尚未发现遗传性TLR 7过表达，但在具有IFN特征的个体中可能存在类似的机制。 为了解决这些假设，我们将使用具有自身反应性转基因重链的小鼠，并在B细胞发育途径的连续阶段检查B细胞选择。这种策略将使我们能够检查内在改变在B细胞信号传导中的作用，来自先天免疫系统和T细胞的外源性信号有助于对自身抗原的耐受性的初始丧失和抗磷脂应答的永久化。我们的数据还将有助于确定为什么抗磷脂综合征对传统的免疫抑制疗法无效，并有助于提出治疗这种毁灭性综合征的新策略。 我们的第三个假设是，致病性自身抗体单独可引起由Fc受体或补体依赖性机制介导的抗磷脂综合征的表现，但血栓形成需要其他炎症介质来激活内皮。我们将检验这一假设，即这种“二次打击”的一种机制是通过神经酰胺途径介导的内皮细胞死亡。 我们的长期目标是确定有助于诱导和传播抗磷脂综合征的关键途径的相互作用，以便为SLE患者设计最佳的个体化治疗方案。